Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 proof-of-concept study of RTB101 in Parkinson's-disease

Trial Profile

Phase 2 proof-of-concept study of RTB101 in Parkinson's-disease

Planning
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs Dactolisib (Primary)
  • Indications Parkinson's disease
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 13 Nov 2018 According to a resTORbio media release, the company expects initiation of this trial by the end of the first quarter of 2019.
    • 09 Aug 2018 According to a resTORbio media release, this trial is anticipated to start by the first quarter 2019.
    • 05 Apr 2018 Patient gender and indication are assumed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top